Delisting risk
Satellos Bioscience
Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.
$8.83
After-hours close−0.05 (−0.62%)
At close$8.89(−7.54%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 589.72%Insiders —
Shares outstanding 1.29M · Float 1.06M · 82.6% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Institutions13F, as of Mar 31, 2026
31 holders · 7.60M shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Franklin Resources Inc | 938.7K | 72.86% | May 13, 2026 | |
| Siren, L.L.C. | 892.1K | 69.25% | May 14, 2026 | |
| Vivo Capital, LLC | 813.7K | 63.16% | May 20, 2026 | |
| Point72 Asset Management, L.P. | 690.8K | 53.62% | May 15, 2026 | |
| Woodline Partners LP | 500.4K | 38.85% | May 15, 2026 | |
| Sphera Funds Management Ltd. | 489.2K | 37.97% | May 15, 2026 | |
| Suvretta Capital Management, LLC | 475.0K | 36.87% | May 15, 2026 | |
| Soleus Capital Management, L.P. | 414.4K | 32.16% | May 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.